BBI 3000

Drug Profile

BBI 3000

Alternative Names: BBI-3000

Latest Information Update: 28 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Undisclosed
  • Developer Brickell Biotech
  • Class Retinoids; Small molecules
  • Mechanism of Action Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acne; Cutaneous T cell lymphoma

Most Recent Events

  • 27 Oct 2017 Brickell Biotech announces intention to submit IND in 2018 (Brickell Biotech pipeline, October 2017)
  • 24 Oct 2017 Preclinical trials in Cutaneous T-cell lymphoma in USA (PO) before October 2017 (Brickell Biotech pipeline, October 2017)
  • 27 Jan 2016 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top